Stock Yards Bank & Trust Co. Sells 2,295 Shares of Humana Inc. (NYSE:HUM)

Stock Yards Bank & Trust Co. lowered its stake in Humana Inc. (NYSE:HUM) by 20.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 9,067 shares of the insurance provider’s stock after selling 2,295 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Humana were worth $2,300,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HUM. International Assets Investment Management LLC increased its stake in shares of Humana by 261,025.1% during the third quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock valued at $2,340,660,000 after buying an additional 738,701 shares during the period. FMR LLC increased its stake in shares of Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after buying an additional 643,291 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Humana by 55.6% during the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock valued at $190,145,000 after buying an additional 214,535 shares during the period. Pzena Investment Management LLC increased its stake in shares of Humana by 8.1% during the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after buying an additional 187,903 shares during the period. Finally, Worldquant Millennium Advisors LLC purchased a new position in shares of Humana during the third quarter valued at approximately $50,102,000. Institutional investors own 92.38% of the company’s stock.

Humana Stock Down 1.2 %

HUM stock opened at $293.40 on Monday. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The business’s 50-day moving average is $275.36 and its two-hundred day moving average is $301.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The company has a market cap of $35.33 billion, a price-to-earnings ratio of 25.99, a P/E/G ratio of 2.21 and a beta of 0.56.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HUM shares. Truist Financial boosted their target price on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Jefferies Financial Group cut Humana from a “buy” rating to a “hold” rating and reduced their price target for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and upped their price target for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. TD Cowen upped their price target on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Finally, Barclays upped their price target on Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 22nd. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $297.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.